Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the efficacy, safety and tolerability of SHAPE administered topically to skin lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL).
Cutaneous T-Cell Lymphoma (CTCL)
DRUG: SHAPE
Lesion severity using CAILS (Composite Assessment of Index Lesion Severity), Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).
modified Severity Weighted Assessment Tool (mSWAT), Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).|Patient assessment of pruritis using a Visual Analog Scale (VAS), Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).|Skindex-29 Quality of Life Tool, Every 4 weeks for 26 weeks|modified Composite Assessment of Index Lesion Severity (CAILS), Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).
This is a Phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of SHAPE Gelled Solution applied topically daily or twice daily for 26 consecutive weeks to specified skin lesions in patients with Stage IA, IB or IIA CTCL. Patients responding to treatment will be allowed to continue on study for a maximum of 52 weeks.